<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03541980</url>
  </required_header>
  <id_info>
    <org_study_id>2017.48</org_study_id>
    <nct_id>NCT03541980</nct_id>
  </id_info>
  <brief_title>Does IV Acetaminophen Reduce Opioid Requirement in Pediatric Patients With Acute Sickle Cell Crises?</brief_title>
  <official_title>Does IV Acetaminophen Reduce Opioid Requirement in Pediatric Emergency Department Patients With Acute Sickle Cell Crises?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Newark Beth Israel Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Newark Beth Israel Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether IV acetaminophen can decrease the need for&#xD;
      subsequent opioid administration in the acute management of sickle cell crisis pain in the&#xD;
      pediatric emergency room.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, prospective, randomized, double-blinded, controlled study in an&#xD;
      academic urban pediatric emergency department of children with sickle cell disease presenting&#xD;
      with acute sickle cell crisis pain between ages of 4 to 16 years, with a pain score of 6/10&#xD;
      or higher on the Wong-Baker modified FACES pain scale. In order to detect a difference of 0.2&#xD;
      mg/kg in cumulative dosage of morphine (at our institution, 0.3 mg/kg morphine deems an&#xD;
      inpatient admission for parenteral pain management) with 80% power and alpha of 0.05, we&#xD;
      calculated a sample size of 33 patients in each group. All patients will receive IV ketorolac&#xD;
      and IV morphine. Patients will be randomized to receive IV acetaminophen or IV saline&#xD;
      (volume-equivalent). Pain scores will be obtained at baseline, and again at 30 minutes, 60&#xD;
      minutes, 90 minutes, and 120 minutes after medication administration. Cumulative morphine&#xD;
      dosing, rates of admission, and rates of adverse effects of morphine will also be analyzed.&#xD;
      Our primary objective is to decrease the need for subsequent opioid administration. Our&#xD;
      secondary objectives are to determine if IV Acetaminophen decreases pain score at 30 minutes,&#xD;
      60 minutes, 90 minutes, and 120 minutes, decreases the rate of admissions, and decreases the&#xD;
      rate of adverse effects from opioids.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 20, 2018</start_date>
  <completion_date type="Actual">February 20, 2020</completion_date>
  <primary_completion_date type="Actual">February 20, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative Opioid Dosing</measure>
    <time_frame>120 minutes</time_frame>
    <description>Total dosing of opioid given after initial evaluation in mg/kg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Scores</measure>
    <time_frame>at disposition</time_frame>
    <description>Scale of 1-10 Pain scale, Min value 1, Max value 10, higher score is worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inpatient Admission</measure>
    <time_frame>120 minutes</time_frame>
    <description>Percentage of patients admitted to the inpatient unit for parenteral pain management</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Effects</measure>
    <time_frame>120 minutes</time_frame>
    <description>Rate of adverse effects experienced by patients from opioid administration vs acetaminophen administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of the Patients Reporting Satisfaction</measure>
    <time_frame>120 minutes</time_frame>
    <description>How satisfied were patients with the management of their pain</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Sickle Cell Anemia Crisis</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients allocated to receive IV acetaminophen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients allocated to receive IV normal saline placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>Administration of 15 mg/kg (1000 mg max dose) of IV acetaminophen</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Ofirmev</other_name>
    <other_name>Tylenol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Normal saline volume equivalent</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sodium chloride solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any patient age 4-16 years with sickle cell disease who presents the Pediatric ER with&#xD;
             acute sickle cell pain crisis with a pain of 6/10 or higher&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with fever (38C or 100.4F)&#xD;
&#xD;
          -  Patient less than age 4 years&#xD;
&#xD;
          -  Patient greater than age 16 years&#xD;
&#xD;
          -  Patient with hypersensitivity/allergy to either morphine, NSAIDs, or acetaminophen&#xD;
&#xD;
          -  Patient received acetaminophen within the past 4 hours&#xD;
&#xD;
          -  Patient with known liver disease or renal disease&#xD;
&#xD;
          -  Patient not requiring IV morphine (pain score 5/10 or less)&#xD;
&#xD;
          -  Patient enrolled in the study within the past 72 hours&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cena Tejani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of NJ at Newark Beth Israel Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Newark Beth Israel</name>
      <address>
        <city>Newark</city>
        <state>New York</state>
        <zip>07112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 17, 2018</study_first_submitted>
  <study_first_submitted_qc>May 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2018</study_first_posted>
  <results_first_submitted>October 15, 2020</results_first_submitted>
  <results_first_submitted_qc>March 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 2, 2021</results_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Newark Beth Israel Medical Center</investigator_affiliation>
    <investigator_full_name>Cena Tejani</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>sickle cell</keyword>
  <keyword>acetaminophen in pain crises</keyword>
  <keyword>opioid-sparing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT03541980/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intervention</title>
          <description>Patients allocated to receive IV acetaminophen-35&#xD;
Acetaminophen: Administration of 15 mg/kg (1000 mg max dose) of IV acetaminophen</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Patients allocated to receive IV normal saline placebo-36&#xD;
Normal saline: Normal saline volume equivalent</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention</title>
          <description>Patients allocated to receive IV acetaminophen&#xD;
Acetaminophen: Administration of 15 mg/kg (1000 mg max dose) of IV acetaminophen</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Patients allocated to receive IV normal saline placebo&#xD;
Normal saline: Normal saline volume equivalent</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="71"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Opioid Dosing</title>
        <description>Total dosing of opioid given after initial evaluation in mg/kg</description>
        <time_frame>120 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Patients allocated to receive IV acetaminophen&#xD;
Acetaminophen: Administration of 15 mg/kg (1000 mg max dose) of IV acetaminophen&#xD;
.2mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients allocated to receive IV normal saline placebo&#xD;
Normal saline: Normal saline volume equivalent&#xD;
.2mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Opioid Dosing</title>
          <description>Total dosing of opioid given after initial evaluation in mg/kg</description>
          <units>mg/kg</units>
          <param>Mean</param>
          <dispersion>99% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".2" lower_limit=".1" upper_limit=".2"/>
                    <measurement group_id="O2" value=".2" lower_limit=".1" upper_limit=".2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Scores</title>
        <description>Scale of 1-10 Pain scale, Min value 1, Max value 10, higher score is worse</description>
        <time_frame>at disposition</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Patients allocated to receive IV acetaminophen&#xD;
Acetaminophen: Administration of 15 mg/kg (1000 mg max dose) of IV acetaminophen 5.5</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients allocated to receive IV normal saline placebo&#xD;
Normal saline: Normal saline volume equivalent 5.2</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores</title>
          <description>Scale of 1-10 Pain scale, Min value 1, Max value 10, higher score is worse</description>
          <units>pain intensity measured on scale 1-10</units>
          <param>Mean</param>
          <dispersion>99% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="4.3" upper_limit="6.6"/>
                    <measurement group_id="O2" value="5.2" lower_limit="4.2" upper_limit="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inpatient Admission</title>
        <description>Percentage of patients admitted to the inpatient unit for parenteral pain management</description>
        <time_frame>120 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Patients allocated to receive IV acetaminophen&#xD;
Acetaminophen: Administration of 15 mg/kg (1000 mg max dose) of IV acetaminophen</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients allocated to receive IV normal saline placebo&#xD;
Normal saline: Normal saline volume equivalent</description>
          </group>
        </group_list>
        <measure>
          <title>Inpatient Admission</title>
          <description>Percentage of patients admitted to the inpatient unit for parenteral pain management</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Effects</title>
        <description>Rate of adverse effects experienced by patients from opioid administration vs acetaminophen administration</description>
        <time_frame>120 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Patients allocated to receive IV acetaminophen-35&#xD;
Acetaminophen: Administration of 15 mg/kg (1000 mg max dose) of IV acetaminophen</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients allocated to receive IV normal saline placebo-36&#xD;
Normal saline: Normal saline volume equivalent</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Effects</title>
          <description>Rate of adverse effects experienced by patients from opioid administration vs acetaminophen administration</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of the Patients Reporting Satisfaction</title>
        <description>How satisfied were patients with the management of their pain</description>
        <time_frame>120 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Patients allocated to receive IV acetaminophen-35&#xD;
Acetaminophen: Administration of 15 mg/kg (1000 mg max dose) of IV acetaminophen</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients allocated to receive IV normal saline placebo-36&#xD;
Normal saline: Normal saline volume equivalent</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of the Patients Reporting Satisfaction</title>
          <description>How satisfied were patients with the management of their pain</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>99% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="77.2" upper_limit="91.8"/>
                    <measurement group_id="O2" value="85" lower_limit="76.2" upper_limit="93.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>120 minutes</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intervention</title>
          <description>Patients allocated to receive IV acetaminophen&#xD;
Acetaminophen: Administration of 15 mg/kg (1000 mg max dose) of IV acetaminophen&#xD;
none</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Patients allocated to receive IV normal saline placebo&#xD;
Normal saline: Normal saline volume equivalent&#xD;
none</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Cena Tejani</name_or_title>
      <organization>Newark Beth Israel Medical Center</organization>
      <phone>973 926 7337</phone>
      <email>ctejani5@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

